Impact of sunitinib treatment on blood glucose levels in patients with metastatic renal cell carcinoma

Japanese Journal of Clinical Oncology

Volumn 42, Issue 4, 2012, Pages 314-317

  Oh, Jong Jin ^a   Hong, Sung Kyu ^a   Joo, Young Min ^a   Lee, Byung Ki ^a   Min, Sun Ho ^a   Lee, Sangchul ^a   Byun, Seok Soo ^a   Lee, Sang Eun ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Diabetes mellitus; Glucose level; Renal cell carcinoma; Suntinib

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MALE; MOUTH ULCER; MUCOSA INFLAMMATION; SIDE EFFECT; STOMATITIS; TASTE DISORDER; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANGIOGENESIS INHIBITORS; BLOOD GLUCOSE; CARCINOMA, RENAL CELL; DIABETES MELLITUS; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES;

EID: 84859241996     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hys002     Document Type: Article

References (13)

1. Di Lorenzo G, Autorino R, Sternberg CN. Metastatic renal cell carcinoma: recent advances in the targeted therapy era. Eur Urol 2009;56:959-71.
2. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
3. Bhojani N, Jeldres C, Patard JJ, Perrotte P, Suardi N, Hutterer G, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008;53:917-30.
4. Billemont B, Medioni J, Taillade L, Helley D, Meric JB, Rixe O, et al. Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer 2008;99:1380-2.
5. Agostino N, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 2010; doi:10.1177/1078155210378913.
6. Templeton A, Brandle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol 2008;19:824-5.
7. Rachdi L, El Ghazi L, Bernex F, Panthier JJ, Czernichow P, Scharfmann R. Expression of the receptor tyrosine kinase KIT in mature beta-cells and in the pancreas in development. Diabetes 2001;50:2021-8.
8. Krishnamurthy M, Ayazi F, Li J, Lyttle AW, Woods M, Wu Y, et al. c-Kit in early onset of diabetes: a morphological and functional analysis of pancreatic beta-cells in c-KitW-v mutant mice. Endocrinology 2007;148:5520-30.
9. Kamba T, Tam BY, Hashizume H, Haskell A, Sennino B, Mancuso MR, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76.
10. Hagerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J 2007;21: 618-28.
11. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. N Engl J Med 2005;352:1049-50.
12. Hagerkvist R, Jansson L, Welsh N. Imatinib mesylate improves insulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci (Lond) 2008;114:65-71.
13. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA 2008;105:18895-900.